OncoMatch

OncoMatch/Clinical Trials/NCT03941561

S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)

Is NCT03941561 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including S-1 for 9 months and S-1 for 1 year for gastric cancer.

Phase 3RecruitingFudan UniversityNCT03941561Data as of May 2026

Treatment: S-1 for 9 months · S-1 for 1 yearThe study aims to compare the efficacy and safety of S-1 for 9 months versus S-1 for 1 year as adjuvant chemotherapy after D2 resection in patients with gastric cancer. Hypothesis: For gastric patients after D2 resection, S-1 for 9 months shows non-inferiority to S-1 for 1 year in disease-free survival(DFS), overall survival (OS) and safety.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Disease stage

Required: Stage II

Excluded: Stage I, III, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: R0 surgery with lymphadenectomy

R0 surgery with lymphadenectomy

Cannot have received: anti-cancer drugs therapy

Patients (within 4 weeks) are receiving any other anti-cancer drugs therapy

Cannot have received: biological therapy

Patients (within 4 weeks) are receiving...biological therapy

Cannot have received: radiation therapy

Patients (within 4 weeks) are receiving...radiation therapy

Cannot have received: immunosuppressive therapy

Patients (within 4 weeks) are receiving...Immunosuppressive therapy

Lab requirements

Blood counts

WBC≥4.0 x 10^9 /L, NEU≥1.5 x 10^9 /L, PLT≥100 x 10^9 /L and HGB≥90g/L

Kidney function

normal kidney function

Liver function

normal liver function

Cardiac function

electrocardiogram normal; severe heart disease excluded

No contraindications to chemotherapy, including normal peripheral blood routine, liver, and kidney function and electrocardiogram (WBC≥4.0 x 10^9 /L, NEU≥1.5 x 10^9 /L, PLT≥100 x 10^9 /L and HGB≥90g/L). With severe heart disease, including congestive heart failure, uncontrolled arrhythmias, unstable angina, myocardial infarction, severe heart valve disease, and resistant hypertension [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify